A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 962 participants.

Also called NCT06192108

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 962 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06192108
Other papers using this trial's data
  • Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial Lancet (London, England), 2026-07-11 DOI, PubMed 42259339

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China, Germany, Mexico, Poland, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06192108. Randomized; no masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2025-09-26 (actual). Results posted on 2026-10-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Acronym
ACHIEVE-2
Intervention (Drug)
Orforglipron
Intervention (Drug)
Dapagliflozin
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06192108
Content hash
d843e7e3e89930ac63453c68c3ca3e71f5a147e8041c8e15c39989b36d0c88f6